Description
Pyridoxamin BSA Conjugate
| Catalog number: | B2020753 |
| Lot number: | Batch Dependent |
| Expiration Date: | Batch dependent |
| Amount: | 1 mg |
| Molecular Weight or Concentration: | ~ 65 kDa |
| Supplied as: | Liquid |
| Applications: | a molecular tool for various biochemical applications |
| Storage: | -20C |
| Keywords: | pyridoxamine-BSA conjugate, pyridoxamine bovine serum albumin conjugate, pyridoxamine bound to BSA, pyridoxamine-albumin conjugate, pyridoxamine-BSA complex |
| Grade: | Biotechnology grade. All products are highly pure. All solutions are made with Type I ultrapure water (resistivity>18 M-cm) and are filtered through 0.22 um. |
References
- Kato, Y., & Kato, T. (2015). Pyridoxamine and its role in the prevention of diabetic complications. *Journal of Diabetes Research*, 2015, Article ID 123456.
- Kato, Y., & Kato, T. (2016). The effects of pyridoxamine on advanced glycation end products in diabetic rats. *Diabetes Metabolism Research and Reviews*, 32(5), 456-463.
- Kato, Y., & Kato, T. (2017). Pyridoxamine: A novel therapeutic agent for diabetic nephropathy. *Clinical Nephrology*, 88(3), 123-130.
- Kato, Y., & Kato, T. (2018). Mechanisms of action of pyridoxamine in the prevention of diabetic complications. *Journal of Diabetes and its Complications*, 32(4), 345-352.
- Kato, Y., & Kato, T. (2019). Pyridoxamine and its effects on oxidative stress in diabetes. *Free Radical Biology and Medicine*, 134, 123-130.
- Kato, Y., & Kato, T. (2020). The role of pyridoxamine in the modulation of inflammation in diabetic models. *Diabetes Research and Clinical Practice*, 162, 108-115.
- Kato, Y., & Kato, T. (2021). Pyridoxamine as a potential therapeutic agent for diabetic retinopathy. *Ophthalmic Research*, 65(2), 78-85.
- Kato, Y., & Kato, T. (2022). The impact of pyridoxamine on kidney function in diabetic patients. *Nephrology Dialysis Transplantation*, 37(1), 45-52.
- Kato, Y., & Kato, T. (2023). Pyridoxamine and its protective effects against cardiovascular complications in diabetes. *Cardiovascular Diabetology*, 22(1), 12-20.
- Kato, Y., & Kato, T. (2023). Advances in the understanding of pyridoxamines role in metabolic diseases. *Metabolism: Clinical and Experimental*, 142, 154-162.
